Synthetic cannabinoids induce autophagy and mitochondrial apoptotic pathways in human glioblastoma cells independently of deficiency in TP53 or pten tumor suppressors

Abstract

Glioblastomas (GBMs) are aggressive brain tumors with frequent genetic alterations in TP53 and PTEN tumor suppressor genes rendering resistance to standard chemotherapeutics. Cannabinoid type 1 and 2 (CB1/CB2) receptor expression in GBMs and antitumor activity of cannabinoids in glioma cells and animal models, raised promises for a targeted treatment of these tumors. The susceptibility of human glioma cells to CB2‐agonists and their mechanism of action are not fully elucidated. We determined CB1 and CB2 expression in 14 low‐grade and 21 high‐grade tumor biopsies, GBM‐derived primary cultures and established cell lines. The non‐selective CB receptor agonist WIN55,212‐2 (but not its inactive enantiomer) or the CB2‐selective agonist JWH133 induced apoptosis in patient‐derived glioma cultures and five established glioma cell lines despite p53 and/or PTEN deficiency. Growth inhibitory efficacy of cannabinoids correlated with CB1/CB2 expression (EC50 WIN55,212‐2: 7.36–15.70 μM, JWH133: 12.15–143.20 μM). Treatment with WIN55,212‐2 or JWH133 led to activation of the apoptotic mitochondrial pathway and DNA fragmentation. Synthetic cannabinoid action was associated with the induction of autophagy and knockdown of autophagy genes augmented cannabinoid‐induced apoptotic cell death. The high susceptibility of human glioblastoma cells to synthetic cannabinoids, despite genetic defects contributing to apoptosis resistance, makes cannabinoids promising anti‐glioma therapeutics.